A 24-week pilot study of dual maintenance therapy with raltegravir and lamivudine-Reference-Cited by-同舟云学术

A 24-week pilot study of dual maintenance therapy with raltegravir and lamivudine

Published:2019-10-01 Issue:12 Volume:33 Page:1891-1896
ISSN:0269-9370
Container-title:AIDS
language:en
Short-container-title:

Author:

de Lazzari Elisa,Lonca Montserrat,Rojas Jhon,Gonzalez-Cordon Ana,Blanch Jordi,Inciarte Alexy,Tricas Amparo,Rodriguez Ana,Martinez-Rebollar Maria,Laguno Montserrat,Mallolas Josep,Sanchez-Palomino Sonsoles,Plana Montserrat,Blanco Jose L.,Martinez Esteban

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Infectious Diseases,Immunology,Immunology and Allergy

Reference23 articles.

1. Dolutegravir resistance mutations: lessons from monotherapy studies;Blanco;Curr Opin Infect Dis,2018

2. Dolutegravir plus lamivudine versus dolutegravir plus tenofovir disoproxil fumarate and emtricitabine in antiretroviral-naive adults with HIV-1 infection (GEMINI-1 and GEMINI-2): week 48 results from two multicentre, double-blind, randomised, noninferiority, phase 3 trials;Cahn;Lancet,2018

3. Dolutegravir-based maintenance monotherapy versus dual therapy with lamivudine: a planned 24 week analysis of the DOLAM randomized clinical trial;Blanco;J Antimicrob Chem,2018

4. Dolutegravir plus lamivudine maintains human immunodeficiency virus-1 suppression through week 48 in a pilot randomized trial;Taiwo;Clin Infect Dis,2018

5. A safety evaluation of raltegravir for the treatment of HIV;de Miguel;Expert Opin Drug Saf,2018

Cited by 9 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Efficacy and safety of raltegravir plus lamivudine maintenance therapy;Journal of Antimicrobial Chemotherapy;2023-12-01

2. Weight Change When Initiating, Switching to, and Discontinuing Integrase Strand Transfer Inhibitors in People Living with HIV;AIDS Patient Care and STDs;2023-03-01

3. Weight Changes With Integrase Strand Transfer Inhibitor Therapy in the Management of HIV Infection: A Systematic Review;Annals of Pharmacotherapy;2022-02-08

4. Short Communication: No Significant Changes in Weight and Body Fat Mass in Suppressed HIV-Infected Patients Switched to Dual Combination Lamivudine Plus Dolutegravir or Raltegravir;AIDS Research and Human Retroviruses;2021-03-01

5. Risks and benefits of reducing the number of drugs to treat HIV-1 infection;Expert Opinion on Drug Safety;2021-02-24